Pfizer vaccine against Covid-19: five cases of myocarditis in France

The basics The Agency for Drug Safety states that five cases of myocarditis have been detected in France after vaccination with Pfizer-BioNTech. The health authorities have not yet established a connection.

Much has been said in recent weeks about possible side effects of the AstraZeneca vaccine and the risk of thrombosis. In their update on Friday April 30th, the ANSM (National Drug Safety Agency) focuses on the Pfizer BioNTech vaccine.

If the majority of the 16,030 side effects reported to her are “expected and not serious,” she says five cases of myocarditis (inflammation of the heart muscle) have been reported in France. The cause and effect relationship has not yet been established and the benefit-risk balance of the vaccine has not been questioned. However, it is a “potential signal,” writes the ANSM.

What about other vaccines?

The ANSM is not aware of any new side effects from the Moderna vaccine. She has had 1,283 side effects reported since the vaccination began. Most of these cases are “non-serious local delayed reactions”.

Regarding the AstraZeneca vaccine – now called Vaxzevria – a new case of thrombosis was reported in the last surveillance period. Since the start of vaccination, AstraZeneca doses have accounted for 12,349 cases of adverse reactions, 28 cases of thrombosis, including 8 deaths. The most recently reported cases are patients, on average, 64 years with more digestive thrombosis.

The latest vaccine used in France, the Janssen vaccine from the Johnson & Johnson laboratory, has not yet been studied due to its recent launch in Europe.

Back to top button